Phase II Trial in Adults of Concurrent or Sequential 2009 Pandemic H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations. Vaccine, 33, 163-173. presented at the 01/2015. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25444805. (2015).
Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons >/=18 Years Old. J Infect Dis, 212, 552-561. presented at the 08/2015. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25649171. (2015).
Avian Influenza A/H7N9 Vaccine Mixed with MF59 Adjuvant at the Point-of-Use. A Randomized Clinical Trial of a Pandemic Threat Response. In ID Week 2014. presented at the 08/10/2014, Philadelphia, PA. Retrieved from http://www.idweek.org/post-meeting-tools/. (2014).
Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine with MF59 Adjuvant: A Randomized Clinical Trial. JAMA, 312, 1420-1428. presented at the 10/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25291578. (2014).
Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons. J Infect Dis, 206, 811-820. presented at the 09/2012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22782949. (2012).
Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group. AIDS Res HumRetroviruses, 14, 1365-74. presented at the 2000.. (2000).
NIAID AIDS Vaccine Evaluation Group. Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp 120 prime-boost HIV-1 vaccine. AIDS Res HumRetroviruses, 14, 1365-74. presented at the 2000.. (2000).
Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines. J Infec Dis, 177, 310-319. presented at the 02/1998. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9466516. (1998).